{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:19:57Z","timestamp":1773382797515,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1053\/j.seminoncol.2009.03.007","type":"journal-article","created":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T09:51:11Z","timestamp":1242813071000},"page":"213-226","source":"Crossref","is-referenced-by-count":36,"title":["Acute Leukemia in Adolescents and Young Adults"],"prefix":"10.1053","volume":"36","author":[{"given":"Anjali S.","family":"Advani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan K.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 14","key":"10.1053\/j.seminoncol.2009.03.007_bib1","first-page":"6623","article-title":"Young adults with leukemia in the United States: lack of clinical trial participation and mortality reduction during the last decade [abstract]","volume":"22","author":"Bleyer","year":"2004","journal-title":"J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MOH.0b013e3283034697","article-title":"Progress in the treatment of adults with acute lymphoblastic leukemia","volume":"14","author":"Larson","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3324\/haematol.12466","article-title":"Acute lymphoblastic leukemia in adolescents and young adults in Finland","volume":"93","author":"Usvasalo","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/asheducation-2005.1.123","article-title":"The treatment of adolescents and young adults with acute lymphoblastic leukaemia","author":"DeAngelo","year":"2005","journal-title":"Am Soc Hematol Educ Book"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib5","first-page":"196","article-title":"Philadelphia chromosome positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker-Walker","year":"1991","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2141.1996.d01-1946.x","article-title":"TEL-AML1 fusion in acute lymphoblastic leukaemia of adults","volume":"95","author":"Aguiar","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V90.2.571","article-title":"Incidence and clinical relevance of TEL\/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials","volume":"90","author":"Borkhardt","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib8","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2003.09.005","article-title":"Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?","volume":"39","author":"Jeha","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib9","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V80.5.1316.1316","article-title":"Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukaemia: a Pediatric Oncology Group study","volume":"80","author":"Whitehead","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib10","series-title":"Cancer in adolescents and young adults","first-page":"83","article-title":"Acute Lymphoblastic leukemia","author":"Nachman","year":"2007"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05544.x","article-title":"Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia","volume":"130","author":"Nachman","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib14","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","article-title":"In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia","volume":"90","author":"Kaspers","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib15","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood-2004-03-0954","article-title":"Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia","volume":"104","author":"Roman-Gomez","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols?","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults?","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs. adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib19","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8","article-title":"Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols","volume":"71","author":"Nachman","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib20","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Program Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V110.11.587.587","article-title":"A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukaemia [abstract]","volume":"110","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib22","first-page":"7005","article-title":"For the Group for Research on Adult ALL (GRAALL)","volume":"26","author":"Huget","year":"2008","journal-title":"J Clin Oncol ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib23","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1182\/blood-2008-04-149088","article-title":"Chemotherapy or allografting for young adults with high-risk ALL? Response","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cncr.20532","article-title":"Death during induction therapy and first remission of acute leukemia in childhood","volume":"101","author":"Rubnitz","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib25","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","article-title":"Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group","volume":"18","author":"Mattano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCF) 1992 trial","volume":"101","author":"Kern","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib29","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib30","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib31","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1,065 patients entered into the MRC AML11 Trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib32","first-page":"67","article-title":"Core binding factor leukaemias are a discrete group: experience from MRC AML 10, 11 and 12 trials","volume":"105","author":"Burnett","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib33","doi-asserted-by":"crossref","first-page":"10a","DOI":"10.1182\/blood.V108.11.18.18","article-title":"A sensitive risk score for directing treatment in younger patients with AML","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2005-03-0867","article-title":"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years","volume":"106","author":"Bowen","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib35","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"ITD does matter in leukemia?","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib37","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study group Ulm","volume":"100","author":"Frohling","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib38","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib39","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"Dohner","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib40","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2004.06.060","article-title":"CEBP\u03b1 mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations","volume":"22","author":"Frohling","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib42","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","article-title":"Favorable prognostic significance of CEBP\u03b1 mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukaemia French Association (ALFA)","volume":"100","author":"Preudhomme","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib43","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","article-title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study","volume":"107","author":"Cairoli","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2141.2003.04362.x","article-title":"Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias","volume":"121","author":"Care","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib45","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib46","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1200\/JCO.2008.16.0333","article-title":"Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia","volume":"26","author":"Virappane","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib48","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V96.12.3948","article-title":"Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia","volume":"96","author":"Venditti","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib49","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.V90.6.2465","article-title":"Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients","volume":"90","author":"San Miguel","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib50","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Sievers","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib51","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Kern","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2141.2003.04610.x","article-title":"Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia","volume":"123","author":"Coustan-Smith","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib53","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.leu.2403405","article-title":"MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia","volume":"18","author":"Feller","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib54","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","article-title":"Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group","volume":"24","author":"Langebrake","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/j.seminoncol.2008.04.009","article-title":"Development of minimal residual disease-directed therapy in acute myeloid leukemia","volume":"35","author":"Freeman","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib56","doi-asserted-by":"crossref","first-page":"166A","DOI":"10.1182\/blood.V110.11.541.541","article-title":"Evaluation of prospective detection of PML-RARA and RARA-PML fusion transcripts by real-time quantitative PCR (RQ-PCR) to direct pre-emptive therapy with arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) patients treated in the UK MRC AML15 trial","volume":"110","author":"Grimwade","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib57","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","article-title":"Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia","volume":"89","author":"Hann","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib58","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international Working Group for diagnosis, standardization of response criteria treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib59","doi-asserted-by":"crossref","first-page":"8A","DOI":"10.1182\/blood.V108.11.13.13","article-title":"The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib60","first-page":"533","article-title":"Acute myelogenous leukaemia in adolescent and young adults: what is the optimal therapy?","author":"Arceci","year":"2006","journal-title":"ASCO Educational Book"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.V99.3.759","article-title":"Acute promyelocytic leukemia: evolving therapeutic strategies","volume":"99","author":"Tallman","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib63","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1182\/blood-2004-09-3475","article-title":"Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia","volume":"105","author":"Sanz","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/mdj019","article-title":"Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and\/or chemotherapy","volume":"17;","author":"Ghavamzadeh","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib65","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.03.007_bib66","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:36:16Z","timestamp":1589805376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0093775409000426"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.03.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}